| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
C Robert, L Thomas, I Bondarenko, S O’day, J Weber, C Garbe, C Lebbe, …
New England Journal of Medicine 364 (26), 2517-2526
|
2731 |
2011 |
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
C Bokemeyer, I Bondarenko, A Makhson, JT Hartmann, J Aparicio, …
Journal of clinical oncology 27 (5), 663-671
|
1602 |
2008 |
| Risk of natalizumab-associated progressive multifocal leukoencephalopathy
G Bloomgren, S Richman, C Hotermans, M Subramanyam, S Goelz, …
New England Journal of Medicine 366 (20), 1870-1880
|
733 |
2012 |
| RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer
NJ Robert, V Diéras, J Glaspy, AM Brufsky, I Bondarenko, ON Lipatov, …
Journal of Clinical Oncology 29 (10), 1252-1260
|
692 |
2011 |
| Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study
TJ Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, …
Journal of Clinical Oncology 30 (17), 2046-2054
|
602 |
2012 |
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, …
New England Journal of Medicine 371 (20), 1877-1888
|
577 |
2014 |
| Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C Bokemeyer, I Bondarenko, JT Hartmann, F De Braud, G Schuch, …
Annals of Oncology 22 (7), 1535-1546
|
571 |
2011 |
| The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, …
The lancet oncology 16 (1), 25-35
|
498 |
2015 |
| Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer
A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, …
Journal of Clinical Oncology 28 (30), 4594-4600
|
367 |
2010 |
| Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
SJ O’day, M Maio, V Chiarion-Sileni, TF Gajewski, H Pehamberger, …
Annals of Oncology 21 (8), 1712-1717
|
364 |
2010 |
| Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, …
The lancet oncology 15 (2), 143-155
|
359 |
2014 |
| KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
C Bokemeyer, I Bondarenko, JT Hartmann, FG De Braud, C Volovat, …
Journal of Clinical Oncology 26 (15_suppl), 4000-4000
|
357 |
2008 |
| Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non–small-cell lung cancer: final results of a phase III trial
MA Socinski, I Bondarenko, NA Karaseva, AM Makhson, I Vynnychenko, …
Journal of Clinical Oncology 30 (17), 2055-2062
|
321 |
2012 |
| Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M Reck, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, …
Annals of Oncology 24 (1), 75-83
|
305 |
2013 |
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, …
The Lancet 386 (9992), 444-451
|
300 |
2015 |
| RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)
NJ Robert, V Diéras, J Glaspy, A Brufsky, I Bondarenko, O Lipatov, …
Journal of Clinical Oncology 27 (15S), 1005-1005
|
221 |
2009 |
| Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
AC Wolff, AA Lazar, I Bondarenko, AM Garin, S Brincat, L Chow, Y Sun, …
Journal of Clinical Oncology 31 (2), 195-202
|
195 |
2012 |
| Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
KJ O’Byrne, U Gatzemeier, I Bondarenko, C Barrios, C Eschbach, …
The lancet oncology 12 (8), 795-805
|
186 |
2011 |
| First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study
J Bergh, IM Bondarenko, MR Lichinitser, A Liljegren, R Greil, NL Voytko, …
Journal of Clinical Oncology 30 (9), 921-929
|
176 |
2012 |
| Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial
RJ Motzer, D Nosov, T Eisen, I Bondarenko, V Lesovoy, O Lipatov, …
Journal of clinical oncology 31 (30), 3791-3799
|
168 |
2013 |
| Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study
C Bokemeyer, I Bondarenko, A Makhson, JT Hartmann, J Aparicio, …
Journal of Clinical Oncology 25 (18_suppl), 4035-4035
|
152 |
2007 |
| Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial
M Maio, JJ Grob, S Aamdal, I Bondarenko, C Robert, L Thomas, C Garbe, …
Journal of Clinical Oncology 33 (10), 1191-1196
|
151 |
2015 |
| Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)
HJ Schmoll, D Cunningham, A Sobrero, CS Karapetis, P Rougier, …
Journal of Clinical Oncology 30 (29), 3588-3595
|
143 |
2012 |
| Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, …
Cancer Research 72 (24 Supplement), S1-6-S1-6
|
133 |
2012 |
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, …
The Lancet Oncology 17 (4), 425-439
|
124 |
2016 |
| Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study
KJ O’byrne, I Bondarenko, C Barrios, C Eschbach, U Martens, Y Hotko, …
Journal of Clinical Oncology 27 (15S), 8007-8007
|
121 |
2009 |
| Final overall survival: fulvestrant 500mg vs 250mg in the randomized CONFIRM trial
A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, …
Journal of the National Cancer Institute, djt337
|
115 |
2013 |
| Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer
MER O’brien, MA Socinski, AY Popovich, IN Bondarenko, A Tomova, …
Journal of Thoracic Oncology 3 (7), 728-734
|
107 |
2008 |
| A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
M Aapro, H Rugo, G Rossi, G Rizzi, ME Borroni, I Bondarenko, T Sarosiek, …
Annals of oncology 25 (7), 1328-1333
|
106 |
2014 |
| Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.
D Cunningham, NC Tebbutt, I Davidenko, AM Murad, SE Al-Batran, …
Journal of Clinical Oncology 33 (15_suppl), 4000-4000
|
103 |
2015 |
| Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial
RJ Motzer, D Nosov, T Eisen, IN Bondarenko, V Lesovoy, ON Lipatov, …
J Clin Oncol 30 (15), 277S
|
103 |
2012 |
| Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
PJ Hesketh, G Rossi, G Rizzi, M Palmas, A Alyasova, I Bondarenko, …
Annals of Oncology 25 (7), 1340-1346
|
98 |
2014 |
| RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.
A Brufsky, I Bondarenko, V Smirnov, S Hurvitz, E Perez, O Ponomarova, …
Cancer Research 69 (24 Supplement), 42-42
|
98 |
2009 |
| Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity
E Poplin, H Wasan, L Rolfe, M Raponi, T Ikdahl, I Bondarenko, …
Journal of Clinical Oncology 31 (35), 4453-4461
|
95 |
2013 |
| Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study
JA Sparano, AN Makhson, VF Semiglazov, SA Tjulandin, OI Balashova, …
Journal of Clinical Oncology 27 (27), 4522-4529
|
92 |
2009 |
| Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial
A Carrato, A Swieboda-Sadlej, M Staszewska-Skurczynska, R Lim, …
Journal of Clinical Oncology 31 (10), 1341-1347
|
84 |
2013 |
| Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
M Campone, I Bondarenko, S Brincat, Y Hotko, PN Munster, …
Annals of oncology, mdr261
|
62 |
2011 |
| Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1; TRIO-18)
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, …
Cancer Research 74 (19 Supplement), CT101-CT101
|
57 |
2014 |
| Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
I Bondarenko, OA Gladkov, R Elsaesser, A Buchner, P Bias
BMC cancer 13 (1), 386
|
52 |
2013 |
| Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).
TJ Lynch, IN Bondarenko, A Luft, P Serwatowski, F Barlesi, RT Chacko, …
Journal of Clinical Oncology 28 (15_suppl), 7531-7531
|
50 |
2010 |
| Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
LWC Chow, B Xu, S Gupta, A Freyman, Y Zhao, R Abbas, MLV Van, …
British journal of cancer 108 (10), 1985-1993
|
41 |
2013 |
| Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, …
Annals of Oncology 27 (3), 417-423
|
39 |
2016 |
| Abstract S1-4: Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg
A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, …
Cancer Research 72 (24 Supplement), S1-4-S1-4
|
35 |
2012 |
| Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.
JD Wolchok, L Thomas, IN Bondarenko, S O’Day, JS Weber, C Garbe, …
Journal of Clinical Oncology 29 (18_suppl), LBA5-LBA5
|
35 |
2011 |
| Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.
M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, MJ Krzakowski, …
Journal of Clinical Oncology 31 (18_suppl), LBA8011-LBA8011
|
34 |
2013 |
| Anomalous aortic origin of a coronary artery: a report from the Congenital Heart Surgeons Society Registry
JA Poynter, WG Williams, S McIntyre, JA Brothers, ML Jacobs
World Journal for Pediatric and Congenital Heart Surgery 5 (1), 22-30
|
31 |
2014 |
| Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer
NK Ibrahim, KO Yariz, I Bondarenko, A Manikhas, V Semiglazov, …
Clinical Cancer Research 17 (21), 6822-6830
|
31 |
2011 |
| A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
S Ramalingam, G Goss, R Rosell, G Schmid-Bindert, B Zaric, Z Andric, …
Annals of Oncology 26 (8), 1741-1748
|
30 |
2015 |
| Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
S Novello, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, …
European journal of cancer 51 (3), 317-326
|
30 |
2015 |
| Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
GV Scagliotti, I Bondarenko, F Blackhall, F Barlesi, TC Hsia, J Jassem, …
Annals of Oncology 26 (3), 497-504
|
29 |
2015 |
| A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors
A Kellum, A Jagiello-Gruszfeld, IN Bondarenko, R Patwardhan, …
Current medical research and opinion 26 (10), 2339-2346
|
29 |
2010 |
| The immediate results of treating patients with acute early postoperative intestinal obstruction
NM Bondarenko, IV Perets, IN Bondarenko
Klinicheskaia khirurgiia, 20-22
|
29 |
1992 |
| Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
D Schadendorf, MM Amonkar, D Stroyakovskiy, E Levchenko, H Gogas, …
European Journal of Cancer 51 (7), 833-840
|
28 |
2015 |
| carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)
MA Socinski, IN Bondarenko, NA Karaseva
J Clin Oncol 28 (18 Suppl)
|
28 |
2010 |
| A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).
SS Ramalingam, GD Goss, ZG Andric, I Bondarenko, B Zaric, T Ceric, …
Journal of Clinical Oncology 31 (18_suppl), CRA8007-CRA8007
|
27 |
2013 |
| Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in ErbB2+ Metastatic Breast Cancer.
L Chow, S Gupta, D Hershman, Z Jiang, R Epstein, I Bondarenko, …
Cancer Research 69 (24 Supplement), 5081-5081
|
27 |
2009 |
| Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma
C Lebbe, S O’Day, V Chiarion-Sileni, TF Gajewski, H Pehamberger, …
Perspectives in Melanoma XII, 2-4
|
27 |
2008 |
| Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer
CP Belani, N Yamamoto, IM Bondarenko, A Poltoratskiy, S Novello, …
BMC cancer 14 (1), 290
|
26 |
2014 |
| CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.
A Di Leo, G Jerusalem, L Petruzelka, R Torres, I Bondarenko, …
Cancer Research 69 (24 Supplement), 25-25
|
26 |
2009 |
| A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
A Awada, IN Bondarenko, J Bonneterre, E Nowara, JM Ferrero, AV Bakshi, …
Annals of oncology 25 (4), 824-831
|
23 |
2014 |
| Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study
T Eisen, Y Shparyk, N Macleod, R Jones, G Wallenstein, G Temple, …
Investigational new drugs 31 (5), 1283-1293
|
23 |
2013 |
| Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC).
A Brufsky, RR Rivera, SA Hurvitz, IN Bondarenko, V Smirnov, V Valero, …
Journal of Clinical Oncology 28 (15_suppl), 1021-1021
|
23 |
2010 |
| Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma
M Maio, I Bondarenko, C Robert, L Thomas, C Garbe, A Testori, H Lu, …
Asia-pacific Journal of Clinical Oncology 9, 109
|
22 |
2013 |
| Long-term functional health status and exercise test variables for patients with pulmonary atresia with intact ventricular septum: a Congenital Heart Surgeons Society study
T Karamlou, JA Poynter, HL Walters, J Rhodes, I Bondarenko, …
The Journal of thoracic and cardiovascular surgery 145 (4), 1018-1027. e3
|
22 |
2013 |
| Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).
MA Socinski, IN Bondarenko, NA Karaseva, A Makhson, I Vynnichenko, …
Journal of Clinical Oncology 28 (18_suppl), LBA7511-LBA7511
|
22 |
2010 |
| Four-year survival update for metastatic melanoma (mm) patients (pts) treated with ipilimumab (ipi)+ dacarbazine (dtic) on phase 3 study CA184-024
M Maio, I Bondarenko, C Robert, L Thomas, C Garbe, A Testori, S Francis, …
Asia-pacific Journal of Clinical Oncology 8, 303
|
21 |
2012 |
| 3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS
C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann, …
European Journal of Cancer Supplements 5 (4), 236
|
21 |
2007 |
| Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial
A Awada, R Colomer, K Inoue, I Bondarenko, RA Badwe, G Demetriou, …
JAMA oncology 2 (12), 1557-1564
|
20 |
2016 |
| Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients.
T Eisen, Y Shparyk, R Jones, NJ MacLeod, G Temple, H Finnigan, …
Journal of Clinical Oncology 31 (15_suppl), 4506-4506
|
20 |
2013 |
| Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy
C Volovat, OA Gladkov, IM Bondarenko, S Barash, A Buchner, P Bias, …
Clinical breast cancer 14 (2), 101-108
|
19 |
2014 |
| 6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4±cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study
C Bokemeyer, I Bondarenko, JT Hartmann, F DeBraud, G Schuch, …
European Journal of Cancer Supplements 7 (2), 346
|
19 |
2009 |
| Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
JFR Robertson, IM Bondarenko, E Trishkina, M Dvorkin, L Panasci, …
The Lancet 388 (10063), 2997-3005
|
17 |
2017 |
| Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18
RS Finn, JP Crown, J Ettl, M Schmidt, IM Bondarenko, I Lang, T Pinter, …
Breast Cancer Research 18 (1), 67
|
17 |
2016 |
| Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer
J O’shaughnessy, M Campone, E Brain, P Neven, D Hayes, I Bondarenko, …
Annals of Oncology, mdv487
|
17 |
2015 |
| Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer
P Goss, IN Bondarenko, GN Manikhas, KB Pendergrass, WH Miller Jr, …
Journal of Clinical Oncology 25 (31), 4961-4966
|
17 |
2007 |
| Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer
M Campone, I Bondarenko, S Brincat, RJ Epstein, PN Munster, E Dubois, …
Breast Cancer Research and Treatment 106, S268
|
14 |
2007 |
| Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)–positive metastatic breast cancer: a randomized clinical trial
HS Rugo, A Barve, CF Waller, M Hernandez-Bronchud, J Herson, J Yuan, …
JAMA 317 (1), 37-47
|
13 |
2017 |
| FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18. 2 antibody, as first-line therapy in patients with advanced CLDN18. 2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.
SE Al-Batran, MH Schuler, Z Zvirbule, G Manikhas, F Lordick, A Rusyn, …
Journal of Clinical Oncology 34 (18_suppl), LBA4001-LBA4001
|
13 |
2016 |
| Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors
L Chow, Z Jiang, R Epstein, I Bondarenko, A Awada, C Coughlin, …
Journal of Clinical Oncology 27 (15_suppl), 3557-3557
|
13 |
2009 |
| FALCON: a phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer
MJ Ellis, I Bondarenko, E Trishkina, M Dvorkin, L Panasci, A Manikhas, …
Annals of Oncology 27 (suppl 6), LBA14_PR
|
12 |
2016 |
| Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy
B Leyland-Jones, I Bondarenko, G Nemsadze, V Smirnov, I Litvin, …
Cancer Research 75 (9 Supplement), S5-07-S5-07
|
12* |
2015 |
| Melanoma and other skin tumors
J Sosman, M Sznol, DF McDermott, R Carvajal, DP Lawrence, …
Annals of Oncology 23 (suppl 9), ix361-ix375
|
12 |
2012 |
| Ipilimumab plus dacarbazine in melanoma
KS Wilson, C Robert, L Thomas, I Bondarenko
N Engl J Med 365 (13), 1256
|
12 |
2011 |
| Results of the first randomized phase II study of Cationic Liposomal Paclitaxel (EndoTAGTM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
A Awada, IN Bondarenko, O Tarasova, J Bonneterre, E Nowara, J Ferrero, …
Ann Oncol 21 (8s), viii5
|
12 |
2010 |
| Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.
HS Rugo, A Barve, CF Waller, M Hernandez-Bronchud, J Herson, J Yuan, …
Journal of Clinical Oncology 34 (18_suppl), LBA503-LBA503
|
11 |
2016 |
| A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
T Eisen, AB Loembé, Y Shparyk, N MacLeod, RJ Jones, M Mazurkiewicz, …
British journal of cancer 113 (8), 1140-1147
|
11 |
2015 |
| Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).
J O’Shaughnessy, M Campone, E Brain, P Neven, DF Hayes, …
Journal of Clinical Oncology 32 (15_suppl), 519-519
|
11 |
2014 |
| Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in non-small cell lung cancer: analysis by baseline histology in a phase 2 trial
T Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, …
JOURNAL OF THORACIC ONCOLOGY 6 (6), S660-S661
|
11 |
2011 |
| Abstract P3-14-04: Efficacy and Safety of Neratinib (HKI-272) in Combination with Paclitaxel in Her2+ Metastatic Breast Cancer
L Chow, S Gupta, DL Hershman, R Epstein, I Bondarenko, MLV Van, …
Cancer Research 70 (24 Supplement), P3-14-04-P3-14-04
|
11 |
2010 |
| Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).
N Robert, V Dieras, J Glaspy, A Brufsky, I Bondarenko, O Lipatov, E Perez, …
Cancer Research 69 (24 Supplement), 6084-6084
|
11 |
2009 |
| Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).
NH Dang, M Ogura, S Castaigne, L Fayad, M Jerkeman, JA Radford, …
Journal of Clinical Oncology 32 (15_suppl), 8529-8529
|
10 |
2014 |
| Phase 3 study of atamestane+ toremifene vs. letrozole in advanced breast cancer
PE Goss, IN Bondarenko, GN Manikhas, KB Pendergrass, WH Miller, …
Journal of Clinical Oncology 24 (18_suppl), LBA525-LBA525
|
10 |
2006 |
| Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells
X Niu, J Zhao, J Ma, C Xie, H Edwards, G Wang, JT Caldwell, S Xiang, …
Clinical Cancer Research 22 (17), 4440-4451
|
9 |
2016 |
| A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy
B Leyland-Jones, I Bondarenko, G Nemsadze, V Smirnov, I Litvin, …
Journal of Clinical Oncology 34 (11), 1197-1207
|
9 |
2016 |
| Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
C Volovat, IM Bondarenko, OA Gladkov, R Elsässer, A Buchner, P Bias, …
Springerplus 4 (1), 316
|
9 |
2015 |
| Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
SA Garnett, M Martin, G Jerusalem, L Petruzelka, R Torres, …
Breast cancer research and treatment 138 (1), 149-155
|
9 |
2013 |
| Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.
JH Kim, F Grossi, F De Marinis, M Cobo, JCH Yang, Y Ragulin, …
Journal of Clinical Oncology 30 (15_suppl), 7558-7558
|
9 |
2012 |
| Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
D Miles, D Cameron, I Bondarenko, L Manzyuk, JC Alcedo, RI Lopez, …
European Journal of Cancer 70, 146-155
|
8 |
2017 |
| Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
MA Socinski, IN Bondarenko, NA Karaseva, A Makhson, I Vynnychenko, …
Journal of Clinical Oncology 29 (15_suppl), 7551-7551
|
8 |
2011 |
| 1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p) VEGF-A in patients (pts) receiving first-line paclitaxel (PAC)+/-bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)
D Miles, D Cameron, I Bondarenko, M Lyudmila, JC Alcedo, RI Lopez, …
European Journal of Cancer 51, S287-S288
|
7 |
2015 |
| Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.
SS Ramalingam, B Zaric, T Ceric, TE Ciuleanu, JF Spicer, I Bondarenko, …
Journal of Clinical Oncology 32 (15_suppl), TPS8118-TPS8118
|
7 |
2014 |
| Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in extensive disease-small cell lung cancer (ED-SCLC): Results from a phase 2 trial
M Reck, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, …
JOURNAL OF THORACIC ONCOLOGY 6 (6), S310-S311
|
7 |
2011 |
| Final results from a randomized, double-blind, phase III study of sunitinib plus FOLFIRI vs. placebo plus FOLFIRI in first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
A Carrato, A Swieboda-Sadlej, M Staszewska-Skurczynska, R Lim, …
ANNALS OF ONCOLOGY 21, 19-19
|
7 |
2010 |
| Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel
M Reck, A Mellemgaard, J von Pawel, M Gottfried, I Bondarenko, Y Cheng, …
Lung Cancer 90 (2), 267-273
|
6 |
2015 |
| Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib+ paclitaxel vs trastuzumab+ paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).
A Awada, R Colomer, I Bondarenko, K Inoue, RA Badwe, G Demetriou, …
Journal of Clinical Oncology 33 (15_suppl), 610-610
|
6 |
2015 |
| An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
CF Waller, I Vynnychenko, I Bondarenko, Y Shparyk, JP Hodge, …
Clinical lung cancer 16 (2), 92-99
|
6 |
2015 |
| 5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)
V Dieras, J Glaspy, A Brufsky, I Bondarenko, O Lipatov, EA Perez, S Chan, …
European Journal of Cancer Supplements 7 (2), 265
|
6 |
2009 |
| A look back at 1906—Perspectives on great earthquakes and post-earthquake investigations
DP Schwartz
Seismological Research Letters 77 (2), 123-127
|
6 |
2006 |
| Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer
W Li, J O’Shaughnessy, D Hayes, M Campone, I Bondarenko, I Zbarskaya, …
Clinical Cancer Research 22 (24), 6002-6009
|
5 |
2016 |
| Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D).
M Reck, A Mellemgaard, SV Orlov, MJ Krzakowski, J Von Pawel, …
Journal of Clinical Oncology 32 (15_suppl), 8100-8100
|
5 |
2014 |
| Opsalin: A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P).
MJ Birrer, I Bondarenko, S Tjulandin, I Vergote, D Cibula, I Ray-Coquard, …
Journal of Clinical Oncology 31 (15_suppl), 5516-5516
|
5 |
2013 |
| Absolute neutrophil counts in a study of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy
OA Gladkov, IM Bondarenko, R Elsaesser, A Buchner, P Bias
ANNALS OF ONCOLOGY 23, 500-500
|
5 |
2012 |
| A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non-small cell lung cancer (NSCLC).
CP Belani, N Yamamoto, I Bondarenko, SV Orlov, J Tang, …
Journal of Clinical Oncology 30 (15_suppl), 7551-7551
|
5 |
2012 |
| Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study.
L Thomas, JD Wolchok, C Garbe, C Lebbe, I Bondarenko, K Rodrigues, …
Journal of Clinical Oncology 30 (15_suppl), 8512-8512
|
5 |
2012 |
| A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC).
P Fidias, TA Ciuleanu, O Gladkov, GM Manikhas, IN Bondarenko, …
Journal of Clinical Oncology 28 (18_suppl), LBA7007-LBA7007
|
5 |
2010 |
| Pegylated liposomal doxorubicin (PLD) plus docetaxel significantly improves time to progression (TTP) compared with docetaxel (D) monotherapy in patients with advanced breast cancer (ABC) treated with adjuvant anthracycline: results from a randomized phase 3 study.
J Sparano, A Makhson, V Semiglazov, S Tjulandin, O Balashova, …
Cancer Research 69 (2 Supplement), 80
|
5 |
2009 |
| The opus study: Predictive value of KRAS status on clinical outcome in patients with metastatic colorectal cancer treated with either FOLFOX4 or FOLFOX4 plus cetuximas
G Schuch, I Bondarenko, J Hartmann, F De Braud, C Volovat, J Nippgen, …
ANNALS OF ONCOLOGY 19, 18-18
|
5 |
2008 |
| Острая ранняя послеоперационная непроходимость кишечника
ИС Белый, ЛВ Усенко, ИВ Перец, ИН Бондаренко
К.: Здоров’я
|
5 |
2003 |
| Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer
IM Bondarenko, A Ingrosso, P Bycott, S Kim, CL Cebotaru
BMC cancer 15 (1), 339
|
4 |
2015 |
| 1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D+ T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL
D Schadendorf, MM Amonkar, D Stroyakovskiy, E Levchenko, H Gogas, …
Annals of Oncology 25 (suppl 4), iv377-iv377
|
4 |
2014 |
| A randomized phase II/III study of naptumomab estafenatox plus IFN-α versus IFN-α in advanced renal cell carcinoma.
RE Hawkins, ME Gore, Y Shparyk, V Bondar, O Gladkov, T Ganev, …
Journal of Clinical Oncology 31 (15_suppl), 3073-3073
|
4 |
2013 |
| Phase I/IIb clinical trial comparing PK and safety of trastuzumab and its biosimilar candidate CT-P6
Y Im, D Krasnozhon, I Bondarenko, Z Zvirbule, K Jung, P Oliynychenko, …
Breast 22, S108-S108
|
4 |
2013 |
| A randomized, open-label, phase 2 trial of paclitaxel/carboplatin with or without bavituximab in patients with previously untreated locally advanced or metastatic non-squamous non-small-cell lung cancer
KH Dragnev, SV Attili, R Gagua, MM Jain, I Bondarenko, J Shan
JOURNAL OF THORACIC ONCOLOGY 7 (9), S241-S242
|
4 |
2012 |
| Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (IPI) plus dacarbazine (DTIC) in phase III study CA184-024
M Maio, I Bondarenko, C Robert, L Thomas, C Garbe, A Testori
Ann Oncol 23 (9)
|
4 |
2012 |
| Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K–mutant melanoma: long-term survival and safety analysis of a phase 3 study
GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, …
Annals of Oncology
|
3 |
2017 |
| A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
T Ciuleanu, I Bazin, D Lungulescu, L Miron, I Bondarenko, A Deptala, …
Annals of Oncology 27 (4), 680-687
|
3 |
2016 |
| Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies
IM Bondarenko, P Bias, A Buchner
Supportive Care in Cancer 24 (1), 267-273
|
3 |
2016 |
| A phase iii study of balugrastim versus pegfilgrastim in breast cancer patients receiving chemotherapy with doxorubicin and docetaxel
O Gladkov, V Moiseyenko, IN Bondarenko, Y Shparyk, S Barash, L Adar, …
The oncologist 21 (1), 7-15
|
3 |
2016 |
| Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial).
JA Ajani, M Abramov, V Bondar, I Bondarenko, YV Shparyk, V Gorbunova, …
Journal of Clinical Oncology 33 (15_suppl), 4015-4015
|
3 |
2015 |
| Treatment outcome according to tumor ERCC1 expression status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab
C Bokemeyer, CH Koehne, I Bondarenko, A von Heydebreck, HJ Grote, …
Age 70 (70), 81
|
3 |
2013 |
| A randomized, noninferiority study of recombinant human G-CSF/human serum albumin fusion (CG-10639) and pegfilgrastim in breast cancer patients receiving myelosuppressive therapy.
O Gladkov, V Moiseyenko, IN Bondarenko, JV Shparyk, S Barash, …
Journal of Clinical Oncology 29 (15_suppl), 9083-9083
|
3 |
2011 |
| Способ предупреждения послеоперационной спаечной болезни брюшной полости
АБ Кутовой, ИН Бондаренко
Клин. хирургия 4, 61-63
|
3 |
1993 |
| Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18. 2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18. 2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma
M Schuler, SE Al-Batran, Z Zvirbule, G Manikhas, F Lordick, A Rusyn, …
Annals of Oncology 27 (suppl 6), 614O
|
2 |
2016 |
| Abstract P4-13-01: PALOMA3: Phase 3 trial of fulvestrant with or without palbociclib in pre-and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy—confirmed efficacy and safety
M Cristofanilli, I Bondarenko, J Ro, SA Im, N Masuda, M Colleoni, …
Cancer Research 76 (4 Supplement), P4-13-01-P4-13-01
|
2 |
2016 |
| The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2-metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.
RS Finn, J Crown, I Lang, SO Kulyk, M Schmidt, R Patel, A Thummala, …
Journal of Clinical Oncology 33 (15_suppl), 572-572
|
2 |
2015 |
| Veliparib (ABT-888) or placebo combined with carboplatin and paclitaxel in patients with previously untreated advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC): A randomized phase 3 trial.
MD McKee, I Bondarenko, SZ Guclu, V Gorbunova, L Urban, P Clingan, …
Journal of Clinical Oncology 33 (15_suppl), TPS8107-TPS8107
|
2 |
2015 |
| A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
J Glaspy, T Tang, D Rutty, X Yan, I Bondarenko, D Krasnozhon
Blood 124 (21), 1584-1584
|
2 |
2014 |
| 471PEFFECT OF NINTEDANIB (BIBF 1120) COMBINED WITH STANDARD 2ND-LINE DOCETAXEL IN NSCLC PATIENTS WHO RECEIVED PRIOR PEMETREXED IN LUME-LUNG 1: A RANDOMISED, PLACEBO-CONTROLLED PHASE III TRIAL
A Mellemgaard, S Orlov, M Krzakowski, J von Pawel, M Gottfried, …
Annals of Oncology 25 (suppl 4), iv157-iv157
|
2 |
2014 |
| 473PPRIOR TAXANE USE IN THE LUME-LUNG 1 PHASE III TRIAL AND THE EFFECT ON OUTCOME FOLLOWING 2ND-LINE TREATMENT WITH NINTEDANIB (BIBF 1120) AND DOCETAXEL IN PATIENTS WITH ADVANCED NSCLC
M Krzakowski, A Mellemgaard, S Orlov, J von Pawel, M Gottfried, …
Annals of Oncology 25 (suppl 4), iv158-iv158
|
2 |
2014 |
| Abstract P3-09-01: NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron
HS Rugo, G Rossi, G Rizzi, ME Borroni, V Lorusso, M Karthaus, …
Cancer Research 73 (24 Supplement), P3-09-01-P3-09-01
|
2 |
2013 |
| O1–030phase Ii Study Of Palbociclib (pd-0332991)+ Letrozole Vs Letrozole Alone In First-line Er+/her2-Advanced Breast Cancer
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, J Ro, X Huang, …
Annals of Oncology 24 (suppl 9), ix32-ix33
|
2 |
2013 |
| Overall survival (OS) and progression free survival (PFS) results for a randomized phase 2 trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIB/IV non-small cell lung cancer (NSCLC)
TJ Lynch Jr, J Neal, I Bondarenko, A Luft, P Serwatowski, F Barlesi, …
ANNALS OF ONCOLOGY 21, 126-126
|
2 |
2010 |
| KRAS status and efficacy in the first-line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience
C Bokemeyer, I Bondarenko, J Hartmann
ASCO Annual Meeting
|
2 |
2008 |
| CD103 and Intratumoral Immune Response in Breast Cancer
ZQ Wang, K Milne, H Derocher, JR Webb, BH Nelson, PH Watson
Clinical Cancer Research 22 (24), 6290-6297
|
1 |
2016 |
| Claudin 18.2-a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18. 2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer
F Lordick, M Schuler, SE Al-Batran, Z Zvirbule, G Manikhas, A Rusyn, …
ANNALS OF ONCOLOGY 27
|
1 |
2016 |
| Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients
C Volovat, I Bondarenko, O Gladkov, A Buchner, A Lammerich, U Müller, …
Supportive Care in Cancer 24 (12), 4913-4920
|
1 |
2016 |
| Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer
DR Spigel, I Bondarenko, G Losonczy, J Mezger, H Kalofonos, M Reck, …
Annals of Oncology 27 (suppl 6), LBA45
|
1 |
2016 |
| A randomized phase II/III study of naptumomab estafenatox+ IFNα versus IFNα in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis
RE Hawkins, M Gore, Y Shparyk, V Bondar, O Gladkov, T Ganev, M Harza, …
Clinical Cancer Research 22 (13), 3172-3181
|
1 |
2016 |
| Efficacy of Nintedanib/Docetaxel after Bevacizumab, Pemetrexed or Taxanes Therapy
D Heigener, M Reck, A Mellemgaard, S Orlov, M Krzakowski, J Von Pawel, …
JOURNAL OF THORACIC ONCOLOGY 10 (9), S323-S324
|
1 |
2015 |
| Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy
O Gladkov, V Moiseyenko, IN Bondarenko, Y Shparyk, S Barash, L Adar, …
Medical Oncology 32 (6), 1-10
|
1 |
2015 |
| Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: final results of a Phase 3 trial (901) and efficacy results of a second line tivozanib extension study (902)
T Hutson, D Nosov, P Tomczak, I Bondarenko, O Lipatov, CN Sternberg, …
|
1 |
2015 |
| 358pdvinflunine (vfl) plus capecitabine (cape) for advanced breast cancer (abc) previously treated with or resistant to anthracycline and resistant to taxane: a phase 3 study versus capecitabine
M Martin, Y Demidchik, I Bondarenko, I Siedakov, D Sakaeva, …
Annals of Oncology 25 (suppl 4), iv119-iv119
|
1 |
2014 |
| Randomized, controlled, multicenter, multinational phase 2 study of docetaxel (DCT) or AXL1717 treatment in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC) of non-small cell lung cancer (NSCLC).
M Bergqvist, I Bondarenko, M Thuresson, M Klockare, J Harmenberg
Journal of Clinical Oncology 32 (15_suppl), 8091-8091
|
1 |
2014 |
| Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).
W Li, J O’Shaughnessy, DS Ricci, TW Griffin, TS Kheoh, MK Yu, …
Journal of Clinical Oncology 32 (15_suppl), 520-520
|
1 |
2014 |
| Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).
TE Ciuleanu, I Bazin, D Lungulescu, L Miron, I Bondarenko, A Deptala, …
Journal of Clinical Oncology 32 (15_suppl), 4029-4029
|
1 |
2014 |
| Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.
MS Aapro, Y Demidchik, I Bondarenko, I Siedakov, D Sakaeva, …
Journal of Clinical Oncology 32 (15_suppl), 1013-1013
|
1 |
2014 |
| PHASE II STUDY OF PALBOCICLIB (PD-0332991)+ LETROZOLE VS LETROZOLE ALONE IN FIRST-LINE ER+/HER2-ADVANCED BREAST CANCER
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, J Ro, X Huang, …
ANNALS OF ONCOLOGY 24, 39-39
|
1 |
2013 |
| Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: An integrated analysis from the phase II and phase III studies
I Bondarenko, P Bias, R Elsaesser, A Buchner
EUROPEAN JOURNAL OF CANCER 49, S443-S444
|
1 |
2013 |
| Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.
I Bondarenko, O Gladkov, R Elaesser, A Buchner, P Bias
Journal of Clinical Oncology 30 (15_suppl), e19587-e19587
|
1 |
2012 |
| Hepatobiliary (HB) safety of eltrombopag administered after carboplatin+ paclitaxel (Carb+ Pac) in patients (pts) with solid tumors
A Kellum, A Jagiello-Gruszfeld, I Bondarenko, R Rafi, P Giangiulio, …
Journal of Clinical Oncology 27 (15S), e20667-e20667
|
1 |
2009 |
| Overall Survival (OS) and New Patterns of Response in Patients (Pts) With Advanced Melanoma Treated With Ipilimumab
S O’Day, R Ibrahim, V De Pril, M Maio, VC Sileni, TF Gajewski, …
23rd Annual Meeting of the International-Society-for-Biological-Therapy-of …
|
1 |
2008 |
| Острая послеоперационная печеночно–почечная недостаточность у хирургических больных
ВП Ужва, ИН Бондаренко
Вестн. хирургии 144 (5), 120-122
|
1 |
1990 |
| A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.
XB Pivot, I Bondarenko, M Dvorkin, E Trishkina, JH Ahn, SA Im, …
Journal of Clinical Oncology 35 (15_suppl), 509-509
|
|
2017 |
| Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2–advanced breast cancer (PALOMA-1; TRIO-18).
RS Finn, J Crown, I Lang, K Boer, I Bondarenko, SO Kulyk, J Ettl, R Patel, …
Journal of Clinical Oncology 35 (15_suppl), 1001-1001
|
|
2017 |
| ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1-or BRCA2-mutated, relapsed, high-grade ovarian carcinoma.
AM Oza, D Lorusso, A Oaknin, T Safra, E Swisher, I Bondarenko, …
Journal of Clinical Oncology 35 (15_suppl), TPS5603-TPS5603
|
|
2017 |
| Elsiglutide in the primary prevention of chemotherapy (CT)-induced diarrhea in patients with colorectal cancer (CRC) receiving 5-fluorouracil (5-FU)-based CT: A multinational, randomized, double-blind, placebo-controlled study.
M Karthaus, M Fedyanin, I Bondarenko, S Chessari, R Spezia, R Giorgino
Journal of Clinical Oncology 35 (15_suppl), 10101-10101
|
|
2017 |
| Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer.
EL Roca, Y Vinnyk, I Bondarenko, YV Shparyk, GM Bariani, K Abdalla, …
Journal of Clinical Oncology 35 (15_suppl), e14065-e14065
|
|
2017 |
| NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
M Aapro, M Karthaus, L Schwartzberg, I Bondarenko, T Sarosiek, …
Supportive Care in Cancer 25 (4), 1127-1135
|
|
2017 |
| PAGE VIEWS
M Reck, D Rodríguez-Abreu, AG Robinson, A Sandler, R Gray, MC Perry, …
N Engl J Med 2017 (376), 996-997
|
|
2017 |
| Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer
M Bergqvist, G Holgersson, I Bondarenko, E Grechanaya, A Maximovich, …
Acta Oncologica 56 (3), 441-447
|
|
2017 |
| Abstract P4-22-02: Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+ TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+ C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer
V Diéras, HS Han, ME Robson, M Palácová, PK Marcom, A Jager, …
Cancer Research 77 (4 Supplement), P4-22-02-P4-22-02
|
|
2017 |
| Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+ C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study
HS Han, V Diéras, ME Robson, M Palácová, PK Marcom, A Jager, …
Cancer Research 77 (4 Supplement), S2-05-S2-05
|
|
2017 |
| Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V plus TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer
V Dieras, HS Han, ME Robson, M Palacova, PK Marcom, A Jager, …
CANCER RESEARCH 77
|
|
2017 |
| 111P BMI effect prognostic features of breast cancer treatments
MI Hojouj, I Bondarenko
Annals of Oncology 27 (suppl_9), mdw576. 013
|
|
2016 |
| 220O Claudin 18.2–a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18. 2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer
F Lordick, M Schuler, SE Al-Batran, Z Zvirbule, G Manikhas, A Rusyn, …
Annals of Oncology 27 (suppl_9)
|
|
2016 |
| Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab
H Rugo, A Barve, CF Waller, M Bronchud, J Herson, J Yuan, A Manikhas, …
Annals of Oncology 27 (suppl 6), LBA16
|
|
2016 |
| Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study
D Heigener, M Gottfried, J Bennouna, I Bondarenko, JY Douillard, …
Annals of Oncology 27 (suppl 6), 1276P
|
|
2016 |
| The role of tumor molecular subtypes in formation of personalized approach to the theatment of breast cancer.
IN Bondarenko, MH Elhajj, KO Chebanov, AV Phokhach, YN Bondarenko
Medical Perspectives 21 (2), 81-86
|
|
2016 |
| Expediency of radiation therapy and adjuvant polychemotherapy in surgical treatment of cancer.
MI Khvorostenko, IN Bondarenko, KV Barannikov, YM Khvorostenko, …
Medical Perspectives 21 (2), 77-81
|
|
2016 |
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (vol 17, pg 425, 2016)
M Cristofanilli, NC Turner, I Bondarenko
LANCET ONCOLOGY 17 (4), E136-E136
|
|
2016 |
| The characteristics of side effects of different modes of chemotherapy for breast cancer.
IM Bondarenko, AV Phokhach
Medical Perspectives 21 (1), 23-26
|
|
2016 |
| Особенности побочных эффектов различных режимов химиотерапии рака молочной железы
ИН БОНДАРЕНКО, АВ ПРОХАЧ
Медичні перспективи 21 (1)
|
|
2016 |
| Рак молочной железы. От молекулярной биологии к персонифицированной терапии
ИН Бондаренко, МХ Эльхажж, АВ Прохач, ВФ Завизион, КО Чебанов
Морфологiя 10 (1), 18-25
|
|
2016 |
| ЭНДОСКОПИЯ И МАЛОИНВАЗИВ-НАЯ ХИРУРГИЯ В ДИАГНОСТИКЕ И ЛЕЧЕНИИ ПРЕДОПУХОЛЕВЫХ ЗА-БОЛЕВАНИЙ И РАКА ЖЕЛУДКА НА РАННИХ СТАДИЯХ
ИН Бондаренко, ВЕ МАШТАЛЕР, КВ БАРАННИКОВ, КО ЧЕБАНОВ, …
МОРФОЛОГIЯ 10 (1), 7-17
|
|
2016 |
| Peculiarities of academic motivation of the students of high medical school.
IM Bondarenko, VF Zavizion, VS Kyslytsyna, OI Aseyev, KO Dmytrenko, …
Medical Perspectives 20 (2), 17-25
|
|
2015 |
| Efficacy and safety of adding the retinoid tamibarotene or placebo to paclitaxel/carboplatin for advanced non-small cell lung cancer.
O Arrieta, DJ Levitt, KB Pendergrass, O Gladkov, I Bondarenko, MM Jain, …
Journal of Clinical Oncology 33 (15_suppl), e19034-e19034
|
|
2015 |
| Особливості навчальної мотивації у студентів вищого медичного навчального закладу
ІМ Бондаренко, ВФ Завізіон, ВС Кислицина, ОІ Асєєв, КО Дмитренко, …
Медичні перспективи 20 (2)
|
|
2015 |
| Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer.
MK El Khazhzh, IM Bondarenko, OI Aseyev, IS Shponka, VF Zavizion, …
Medical Perspectives 19 (3), 29-35
|
|
2014 |
| Questa è la versione dell’autore dell’opera
GV Scagliotti, C Gridelli, F de Marinis, M Thomas, M Dediu, JL Pujol, …
Lung Cancer 85 (3), 408-14
|
|
2014 |
| 1494PSAFETY AND TOLERABILITY OF LIPEGFILGRASTIM (LIPEG) AND PEGFILGRASTIM (PEG) IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY (CTX): AN INTEGRATED ANALYSIS OF 2 STUDIES STRATIFIED BY AGE
IM Bondarenko, P Bias, U Müller, A Buchner
Annals of Oncology 25 (suppl 4), iv522-iv522
|
|
2014 |
| ANTIANGIOGENIC-SPECIFIC ADVERSE EVENTS (AES) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NINTEDANIB (N) AND DOCETAXEL (D)
A Mellemgaard, M Reck, S Orlov, M Krzakowski, J Von Pawel, M Gottfried, …
JOURNAL OF THORACIC ONCOLOGY 9 (9), S155-S155
|
|
2014 |
| PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY IN SECOND-LINE ADVANCED NSCLC PATIENTS
A Mellemgaard, JY Douillard, S Novello, R Kaiser, S Orlov, M Krzakowski, …
JOURNAL OF THORACIC ONCOLOGY 9 (9), S152-S153
|
|
2014 |
| 30 Nintedanib (BIBF 1120)+ docetaxel as second-line therapy in patients with stage IIIB/IV or recurrent NSCLC: results of the phase III, randomised, double-blind LUME-Lung 1 trial
M Reck, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, …
Lung Cancer 83, S12
|
|
2014 |
| Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
M Mandalà, M Millward, A Arance, I Bondarenko, J Haanen, …
|
|
2014 |
| C148: Partial versus radical nephrectomy: Analyses of the perioperative complications
S Styopushkin, I Bondarenko, K Chebanov, R Sokolenko, V Chaikovkyi
European Urology Supplements 6 (13), e1331, e1331a
|
|
2014 |
| Особливості діагностики та клінічного перебігу різних імуногістохімічних підтипів раку молочної залози
ЕЛЬХ МХ, ІМ Бондаренко, ОІ Асєєв, ІС Шпонька, ВФ Завізіон, АС Скляр, …
Медичні перспективи 19 (3)
|
|
2014 |
| Evaluation Of Electrocardiogram Parameters In Patients With Breast and Lung Cancer Treated With Chemotherapy and Lipegfilgrastim Or Pegfilgrastim
A Lammerich, I Bondarenko
Blood 122 (21), 4856-4856
|
|
2013 |
| ANALYSIS OF PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY IN SECOND-LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
S Novello, A Mellemgaard, R Kaiser, JY Douillard, S Orlov, M Krzakowski, …
JOURNAL OF THORACIC ONCOLOGY 8, S1207-S1207
|
|
2013 |
| PO120 FACTORS AFFECTING CHANGES IN IMMUNOHISTOCHEMISTRY PHENOTYPE OF BREAST CANCER
O Aseyev, I Bondarenko, M El Hajj, V Zavizion, A Kunnik
The Breast 22, S60
|
|
2013 |
| Somatoform disorders in the family doctor’s practice.
V Prykhodko, I Mikropulo, M Oleinik, E Kononenko, D Moreva, O Gogol, …
Medical Perspectives 18 (3), 15-24
|
|
2013 |
| Incidence of bone pain in patients with breast cancer treated with balugrastim or pegfilgrastim: An integrated analysis from the phase II and III studies
O Gladkov, C Volovat, A Buchner, S Barash, H Voliovitch, T Erez, N Lang, …
EUROPEAN JOURNAL OF CANCER 49, S439-S439
|
|
2013 |
| Analysis of ANC recovery from a Phase III study of lipegfilgrastim versus pegfilgrastim in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
I Bondarenko, P Bias, R Elsaesser, A Buchner
EUROPEAN JOURNAL OF CANCER 49, S434-S435
|
|
2013 |
| Ganetespib in combination with docetaxel versus docetaxel alone in second line adenocarcinoma patients with KRAS mutations and elevated LDH levels
DA Fennell, GD Goss, Z Andric, I Bondarenko, B Zaric, T Ceric, …
EUROPEAN JOURNAL OF CANCER 49, S801-S801
|
|
2013 |
| реДКИй КЛИнИЧеСКИй СЛуЧАй: зернИСто-КЛетоЧнАя МИоБЛАСтоМА (оПуХоЛь АБрИКоСовА) МоЛоЧной жеЛезы
VF Zavizion, IM Bondarenko, IV Bilenky, VA Gurtovyy, OI Aseyev, …
ББК 55.6 ISSN 2307-1575 Отв. секретар–Смирнов ВМ Секретаріат: Золотухин СЄ …
|
|
2013 |
| Вплив системного лікування на імунофенотип раку молочної залози
МХ Ельхажж, ІМ Бондаренко, ВФ Завізіон, АВ Куник, ОІ Асєєв
Університетська клініка, 54-58
|
|
2013 |
| Supportive care
S Clarke, C Tan, J Read, V Phan, JK Peat, P Beale, Y Gornadha, …
Annals of Oncology 23 (suppl 9), ix499-ix527
|
|
2012 |
| Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): Results from an open-label, phase II study.
T Eisen, Y Shparyk, NJ MacLeod, G Wallenstein, G Temple, Y Khder, …
Journal of Clinical Oncology 30 (15_suppl), e15037-e15037
|
|
2012 |
| Tumor Microenvironment
TJ Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko
J Clin Oncol
|
|
2012 |
| Сучасні підходи до викладання онкології як основа вдосконалення навчального процесу
ВФ Завізіон, ІМ Бондаренко
Медичні перспективи 17 (1)
|
|
2012 |
| A NEW METHOD OF MULTIMODALITY TREATINENT OF LOCALLY ADVANCED CANCER OF THE FLOOR OF THE ORAL CAVITY
MP Komskyi, IN Bondarenko, NV Gutorova, OV Kolesnik, KA Kochet
БУКОВИНСЬКИЙ МЕДИЧНИЙ ВІСНИК, 210
|
|
2012 |
| P3-17-06: Final Results of a Controlled, Randomized 3-Arm Phase II Trial of EndoTAG”-1, a Cationic Liposomal Formulation of Paclitaxel Targeting Tumor Endothelial Cells, in Advanced Triple-Negative Breast Cancer (TNBC).
A Awada, IN Bondarenko, O Tarasova, J Bonneterre, E Nowara, …
Cancer Research 71 (24 Supplement), P3-17-06-P3-17-06
|
|
2011 |
| A Second Randomised Ipilimumab Phase Iii Trial Shows Significant Survival Improvement In Metastatic Melanoma
P Hersey, JD Wolchock, L Thomas, IN Bondarenko, S O’day, J Weber, …
Asia-pacific Journal of Clinical Oncology 7, 111
|
|
2011 |
| Application of new methodology to allow comparison of duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial
S Garnett, M Martin, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, …
The Breast 20, S45
|
|
2011 |
| 5079 POSTER The Substantiation of Optimal Approaches to Systemic Treatment for Patients With Metastatic Breast Cancer
O Asevev, K Dmytrenko, I Bondarenko, V Kyslytsyna, V Mashtaler
European Journal of Cancer 47, S354
|
|
2011 |
| PAGE VIEWS
C Robert, L Thomas, I Bondarenko, FS Hodi, SJ O’Day, DF McDermott
N Engl J Med 2011 (365), 1256-1258
|
|
2011 |
| NAB-PACLITAXEL AND CARBOPLATIN COMPARED WITH CREMOPHOR-BASED PACLITAXEL AND CARBOPLATIN IS EFFECTIVE AND SAFE AS FIRST-LINE THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER: FINAL RESULTS OF A PHASE 3 STUDY
MA Socinski, I Bondarenko, N Karaseva, A Makhson, I Vynnychenko, …
JOURNAL OF THORACIC ONCOLOGY 6 (6), S417-S417
|
|
2011 |
| PREDICTING ENDOCRINE THERAPY EFFICACY IN MENOPAUSAL PATIENTS WITH LUMINAL-TYPE ADVANCED BREAST CANCER
O Aseyev, I Bondarenko
ANNALS OF ONCOLOGY 22, 64-64
|
|
2011 |
| mAyo CliniC CARdiology UpdATE 2012
C Robert, L Thomas, I Bondarenko
N Engl J Med 364, 2517-26
|
|
2011 |
| Економічна оцінка протипухлинної терапії метастатичного раку легенів та її ускладнень на прикладі клінічної ситуації
ОВ Зайцева, ВФ Завізіон, ІМ Бондаренко, ОВ Макаренко
Фармакологія та лікарська токсикологія, 21
|
|
2011 |
| Overall Survival and Progression Free Survival Results for a Randomized Phase 2 Trial of Ipilimumab (IPI) and Paclitaxel/Carboplatin (P/C) in First-Line Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
T Lynch, J Neal, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, …
JOURNAL OF THORACIC ONCOLOGY 5 (12), S515-S515
|
|
2010 |
| FIRST LINE SYSTEM THERAPY INDIVIDUALIZATION IN POSTMENOPAUSAL PATIENTS WITH LUMINAL SUBTYPE OF ADVANCED BREAST CANCER
O Aseyev, IN Bondarenko
ANNALS OF ONCOLOGY 21, 43-44
|
|
2010 |
| 476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1
I Bondarenko, J Glaspy, A Brufsky, O Lipatov, EA Perez, S Chan, X Zou, …
European Journal of Cancer Supplements 8 (3), 198
|
|
2010 |
| 496 RIBBON-1: efficacy of capecitabine-bevacizumab in patients with triple-negative metastatic breast cancer (MBC)
H Lindman, O Lipatov, I Bondarenko, L Panasci, R Coleman
European Journal of Cancer Supplements 8 (3), 204
|
|
2010 |
| Botargues J. vi82 (P-0190) Boucça-Machado T. vi90 (P-0218), vi92 (P-0225), vi92 (P-0227) Bouché O. vi51 (P-0078) Bouillet P. vi104 (P-0271)
F Boissiere-Michot, I Bondarenko, F Bosman
|
|
2010 |
| Hepatobiliary (HB) safety of eltrombopag administered after carboplatin plus paclitaxel (Carb plus Pac) in patients (pts) with solid tumors
A Kellum, A Jagiello-Gruszfeld, I Bondarenko, R Rafi, P Giangiulio, …
JOURNAL OF CLINICAL ONCOLOGY 27 (15)
|
|
2009 |
| Impact of pegylated liposomal doxorubicin (PLD) plus docetaxel (D) versus single-agent D on health-related quality of life (HRQOL) of patients with advanced breast cancer (BC) previously treated with neoadjuvant-adjuvant anthracycline
SA Tjulandin, IN Bondarenko, VF Semiglazov, OI Balashova, …
Journal of Clinical Oncology 27 (15_suppl), e20522-e20522
|
|
2009 |
| Weekly paclitaxel in women with metastatic breast cancer
I Bondarenko, K Dmytrenko, V Kyslytsyna
ANNALS OF ONCOLOGY 19, 133-134
|
|
2008 |
| Use of neural networks to forecast efficiency of systemic therapy of advanced breast cancer in menopausal patients
O Aseyev, I Bondarenko
ANNALS OF ONCOLOGY 19, 133-133
|
|
2008 |
| Phase 3 study of atamestane plus toremifene vs. letrozole in advanced breast cancer
PE Goss, IN Bondarenko, GN Manikhas, KB Pendergrass, WH Miller, …
JOURNAL OF CLINICAL ONCOLOGY 24 (18), 932S-932S
|
|
2006 |
| Toremifene in the treatment of metastatic melanoma
S Azatyan, N Zaliznyak, I Bondarenko
ANNALS OF ONCOLOGY 17, 165-165
|
|
2006 |
| Ways of optimization for the plan of treatment of acute appendicitis
NM Bondarenko, AI Novikov, IN Bondarenko
Klinichna khirurhiia/Ministerstvo okhorony zdorov’ia Ukraïny, Naukove …
|
|
2003 |
| The possibilities of application of iodinedicerinum in urgent surgery
AI Novikov, GM Larionov, AK Iarosh, SA Tylik, TM Solov’evskaia, …
Klinichna khirurhiia, 46
|
|
2000 |
| Correction to Lancet Oncol
M Cristofanilli, NC Turner, I Bondarenko
|
|
|
| 2012 ТОМ XVII № 44
ВІ Жилюк, ВЙ Мамчур, ОГ Родинський, ОГ Зінов’єва, АВ Самойленко, …
|
|
|
| 2014 ТОМ XIX № 33
ЕМ Білецька, НМ Онул, ОГ Родинський, ЮВ Козлова, ВО Галаган, …
|
|
|
| Науковий журнал Дніпропетровської державної медичної академії
ОГ Родинський, ВА Гузь, ЛВ Гузь, ОМ Литвинова, АВ Шарун, …
|
|
|
| 71 Radical-Intent Hypofractionated Radiotherapy for Locally Advanced NoneSmall-Cell Lung Cancer: A Systematic Review of the Literature Tyler S. Kaster, Brian Yaremko, David A. Palma, George B. Rodrigues 80 Standard Treatment Option in Stage III NoneSmall-Cell Lung Cancer: Case Against Trimodal Therapy and Consolidation Drug Therapy
B Jeremic, S Li, X Qi, Y Huang, D Liu, F Zhou, C Zhou, CF Waller, …
|
|
|
| RIBBON-1: efficacy of capecitabine plus bevacizumab in patients with triple-negative metastatic breast cancer
H Lindman, O Lipatov, I Bondarenko, L Panasci, R Coleman
Age 462 (153), 65
|
|
